Infective endocarditis caused by Streptococcus agalactiae: time for beta-hemolytic streptococci to follow treatment recommendations for S. aureus?

Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):419-422. doi: 10.1007/s10096-018-03446-2.

Author

Parham Sendi^{1

2}

Affiliations

¹ Institute for Infectious Diseases, University of Bern, Friedbühlstrasse, 51, CH-3001, Bern, Switzerland. Parham.Sendi@ifik.unibe.ch.
² Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University Basel, Basel, Switzerland. Parham.Sendi@ifik.unibe.ch.

PMID: 30680556
DOI: 10.1007/s10096-018-03446-2

No abstract available

Publication types

Editorial

MeSH terms

Animals
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / standards
Anti-Bacterial Agents / therapeutic use*
Endocarditis, Bacterial / drug therapy*
Endocarditis, Bacterial / microbiology
Humans
Microbial Sensitivity Tests
Practice Guidelines as Topic
Staphylococcal Infections / drug therapy*
Staphylococcus aureus / drug effects
Streptococcal Infections / drug therapy*
Streptococcus agalactiae / drug effects

Substances

Anti-Bacterial Agents